David J Brooks Selected Research

Dopamine (Intropin)

1/2021	Brain Microglial Activation Increased in Glucocerebrosidase (GBA) Mutation Carriers without Parkinson's disease.
1/2019	Attenuation of dopamine-induced GABA release in problem gamblers.
10/2017	Assessment of neuroinflammation in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study.
1/2017	Sustained striatal dopamine levels following intestinal levodopa infusions in Parkinson's disease patients.
3/2016	Progression of nonmotor symptoms in subgroups of patients with non-dopamine-deficient Parkinsonism.
1/2016	Molecular imaging of dopamine transporters.
11/2014	Investigating expectation and reward in human opioid addiction with [(11) C]raclopride PET.
1/2013	Ventral striatal dopamine synthesis capacity predicts financial extravagance in Parkinson's disease.
8/2012	The catechol-O-methyltransferase Val(158)Met polymorphism modulates fronto-cortical dopamine turnover in early Parkinson's disease: a PET study.
4/2012	Serotonin neuron loss and nonmotor symptoms continue in Parkinson's patients treated with dopamine grafts.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David J Brooks Research Topics

Disease

85	Parkinson Disease (Parkinson's Disease) 01/2022 - 03/2002
42	Alzheimer Disease (Alzheimer's Disease) 01/2022 - 07/2006
26	Cognitive Dysfunction 01/2022 - 09/2010
21	Dementia (Dementias) 01/2022 - 06/2002
16	Parkinsonian Disorders (Parkinsonism) 01/2021 - 10/2002
15	Dyskinesias (Dyskinesia) 01/2017 - 07/2002
13	Neuroinflammatory Diseases 01/2021 - 05/2015
9	Disease Progression 01/2021 - 01/2005
8	Inflammation (Inflammations) 05/2020 - 01/2012
7	Huntington Disease (Huntington's Disease) 01/2021 - 05/2003
7	Neurodegenerative Diseases (Neurodegenerative Disease) 11/2020 - 04/2005
6	Tremor (Tremors) 01/2021 - 11/2002
5	Multiple System Atrophy 01/2016 - 11/2002
5	Progressive Supranuclear Palsy (Steele Richardson Olszewski Syndrome) 01/2016 - 11/2002
5	Opioid-Related Disorders (Opiate Addiction) 01/2016 - 01/2005
4	Alcoholism (Alcohol Abuse) 01/2016 - 07/2007
4	Corticobasal Degeneration 01/2016 - 11/2002
3	Neurobehavioral Manifestations 01/2020 - 07/2012
3	Atrophy 10/2015 - 07/2006
2	REM Sleep Behavior Disorder 10/2021 - 12/2020
2	Type 2 Diabetes Mellitus (MODY) 01/2021 - 01/2019
2	Amyloidosis 10/2019 - 08/2009
2	Multiple Sclerosis 10/2019 - 10/2019
2	Gambling (Pathological Gambling) 01/2019 - 01/2013
2	Traumatic Brain Injuries (Traumatic Brain Injury) 03/2016 - 12/2015
2	Frontotemporal Dementia (Semantic Dementia) 01/2016 - 05/2015
2	Pathologic Processes 12/2015 - 03/2014
2	Amyloid Plaque 11/2013 - 04/2010
2	Temporal Lobe Epilepsy 10/2013 - 01/2008
2	Seizures (Absence Seizure) 10/2013 - 04/2007
2	Disruptive, Impulse Control, and Conduct Disorders (Kleptomania) 01/2013 - 10/2009
2	Fatigue 11/2010 - 01/2010
2	Essential Tremor (Essential Tremors) 10/2010 - 07/2010
2	Substance-Related Disorders (Drug Abuse) 10/2009 - 05/2006
2	Nausea 02/2008 - 01/2004
2	Movement Disorders (Movement Disorder) 12/2005 - 11/2002
2	Tourette Syndrome (Tourette's Syndrome) 12/2004 - 05/2004
1	Hypokinesia (Bradykinesia) 01/2022
1	Partial Epilepsies (Epilepsy, Partial) 12/2021
1	Olfaction Disorders (Cacosmia) 10/2021

Drug/Important Bio-Agent (IBA)

35	Amyloid (Amyloid Fibrils)IBA 01/2022 - 07/2006
35	Dopamine (Intropin)FDA LinkGeneric 01/2021 - 10/2002
25	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2003
19	Levodopa (L Dopa)FDA LinkGeneric 01/2019 - 06/2002
14	2- (4'- (methylamino)phenyl)- 6- hydroxybenzothiazole (Pittsburgh compound B)IBA 05/2020 - 07/2006
9	Proteins (Proteins, Gene)FDA Link 01/2020 - 01/2014
8	Cholinergic Agents (Cholinergics)IBA 10/2021 - 07/2007
8	fluorodopa F 18IBA 01/2020 - 03/2002
8	PK 11195 (PK11195)IBA 12/2015 - 10/2004
7	Opioid Receptors (Opioid Receptor)IBA 10/2013 - 12/2004
6	DiprenorphineIBA 10/2013 - 01/2005
5	Apolipoproteins E (ApoE)IBA 01/2022 - 10/2014
5	SynucleinsIBA 10/2020 - 03/2015
5	RacloprideIBA 01/2017 - 02/2003
5	Dopamine Agonists (Dopamine Agonist)IBA 01/2017 - 11/2002
5	Pharmaceutical PreparationsIBA 01/2016 - 01/2005
5	Serotonin (5 Hydroxytryptamine)IBA 04/2015 - 06/2010
5	Dihydroxyphenylalanine (Dopa)IBA 09/2013 - 10/2002
4	neuromelaninIBA 10/2021 - 01/2016
4	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 05/2013
4	Dopamine Receptors (Dopamine Receptor)IBA 01/2017 - 05/2003
4	Glial Cell Line-Derived Neurotrophic Factor (GDNF)IBA 09/2013 - 05/2003
4	entacapone (Comtan)FDA Link 04/2009 - 01/2004
4	Flumazenil (Romazicon)FDA LinkGeneric 01/2008 - 06/2003
3	Ion Channels (Ion Channel)IBA 12/2021 - 04/2011
3	Norepinephrine Plasma Membrane Transport Proteins (Norepinephrine Transporter)IBA 10/2021 - 01/2018
3	Norepinephrine (Noradrenaline)FDA LinkGeneric 01/2021 - 04/2012
3	AcetylcholinesteraseIBA 12/2020 - 03/2015
3	Amyloid beta-PeptidesIBA 05/2020 - 04/2010
3	7- (6- fluoropyridin- 3- yl)- 5H- pyrido(4,3- b)indoleIBA 01/2020 - 01/2016
3	Neuroprotective AgentsIBA 01/2019 - 01/2003
3	GABA-A Receptors (GABA(A) Receptor)IBA 01/2016 - 07/2010
3	Serotonin Plasma Membrane Transport Proteins (Serotonin Transporter)IBA 04/2015 - 11/2010
3	Monoclonal AntibodiesIBA 03/2012 - 04/2010
3	Opioid Analgesics (Opioids)IBA 04/2007 - 12/2004
3	ropinirole (Requip)FDA LinkGeneric 11/2006 - 07/2003
3	Methamphetamine (Desoxyn)FDA LinkGeneric 12/2005 - 05/2003
2	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 12/2021 - 04/2011
2	Neurotransmitter Agents (Neurotransmitter)IBA 01/2021 - 01/2010
2	Liraglutide FDA Link 01/2020 - 01/2019
2	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2020 - 01/2019
2	gamma-Aminobutyric Acid (GABA)IBA 01/2019 - 07/2010
2	Carbidopa (Lodosyn)FDA LinkGeneric 01/2017 - 02/2008
2	LigandsIBA 01/2016 - 04/2005
2	Dopamine Plasma Membrane Transport Proteins (Dopamine Transporter)IBA 01/2016 - 09/2011
2	(R)- (11C)1- (2- chlorophenyl)- N- methyl- N- (1- methylpropyl)- 3- isoquinolinecarboxamideIBA 09/2015 - 01/2014
2	flutemetamolIBA 06/2015 - 01/2012
2	NAD (NADH)IBA 10/2013 - 04/2007
2	AD 20 (AD-20)IBA 01/2013 - 09/2010
2	Catechol O-Methyltransferase (Methyltransferase, Catechol)IBA 08/2012 - 01/2004
2	bapineuzumabIBA 03/2012 - 04/2010
2	IronIBA 01/2012 - 07/2009
2	Dopamine Agents (Dopaminergic Agents)IBA 10/2010 - 05/2006
1	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA 01/2022
1	antineoplaston A10 (A 10)IBA 01/2022

Therapy/Procedure

16	Therapeutics 01/2022 - 11/2002
7	Transplantation 06/2013 - 07/2002
2	Denervation 10/2021 - 01/2020
2	Activities of Daily Living (ADL) 01/2019 - 07/2012
2	Parasympathectomy 03/2015 - 11/2014